Natalie Ohana Yivgi

Natalie Ohana Yivgi

Company: Minovia Therapeutics

Job title: Co-Founder & Chief Executive Officer


Natalie is a life science entrepreneur with over 20 years of experience in mitochondrial science. She has founded and is leading Minovia Therapeutics since inception in 2012 to a global organization. Minovia Therapeutics is a clinical stage company developing Mitochondrial Augmentation Therapy (MAT), the first mitochondrial cell therapy platform targeting the root cause of mitochondrial diseases.


Academic background:

  • Post-doctoral fellowship at the Weizmann Institute
  • D. in Biochemistry from The Hebrew University
  • Sc. In Bar Ilan University (Human Biology and IVF)
  • Sc. In Ben Gurion University (Medical Sciences)


  • Fellow at the Termeer Foundation
  • Fellow member at the Merage Institution
  • Member at the 8400 Health network: A cross-sector leaders network actualizing the globally disruptive capability of Israel’s HealthTech ecosystem

Natalie lives in Haifa, Israel and is a proud mother of 4 girls.


Mitochondrial Augmentation Therapy (MAT): Harnessing the power of mitochondria for therapeutic purposes 1:45 pm

• Examine Mitochondrial Augmentation Therapy (MAT) • Preclinical and clinical review of the multi-systemic effect of MAT in mitochondrial diseases • Advance the research of MAT to address far-reaching applicationsRead more

day: Day Two

Panel Discussion: Recognize the Financial Difficulty of Developing Drugs for Targeting Mitochondria & Moving Drugs to the Next Phase 12:00 pm

• Explore the challenges of funding development • Learn how drug developers can inspire and attract companies to invest in their novel development and pipeline • Discover how can the industry come together to overcome the paucity of fundingRead more

day: Day Two

Panel Discussion: Evaluate the Current Challenges, Approaches & Opportunities in Targeting-Mitochondria for Age-related & Mitochondrial Diseases 9:55 am

• How can drug developers/research cut to the real barriers, and debate what is truly required to break through to successful treatments for mitochondrial diseases? • What’s the impact of COVID-19 and its repercussions on existing clinical trials/research?Read more

day: Day One

© Copyright 2018 Hanson Wade | Design and site by Event Engine | Hanson Wade Limited is registered in England & Wales, number 06752216.
Registered Office: Suite A, 6 Honduras Street, London EC1Y 0TH.